Company intelligence / Profile preview
HIPRA
- Ownership
- Private
- Employees
- ~1400
- Development stage
- Commercial
Overview
HIPRA has developed over 100 vaccines for different animal species. Since 2020, the company has been developing a COVID-19 vaccine for humans. In 2021, they acquired GoodGut, a biotech startup focused on diagnostic tests for digestive diseases.
- Therapeutic areas
- OtherGastroenterologyInfectious Diseases
- Modalities
- VaccinesBiologicsDiagnostic services
- Industry
- Veterinary
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on HIPRA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIPRA.